Newron Pharmaceuticals SpA
SIX:NWRN

Watchlist Manager
Newron Pharmaceuticals SpA Logo
Newron Pharmaceuticals SpA
SIX:NWRN
Watchlist
Price: 7.13 CHF -0.7% Market Closed
Market Cap: 142.3m CHF
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one NWRN stock under the Base Case scenario is 14.94 CHF. Compared to the current market price of 7.13 CHF, Newron Pharmaceuticals SpA is Undervalued by 52%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

NWRN Relative Value
Base Case
14.94 CHF
Undervaluation 52%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

2.9
P/S
P/S
Price to Sales
2.9
vs History
98
vs Industry
7
Median 3Y
10.5
Median 5Y
7.2
Industry
2.4
Forward
12.4
More Details
9.5
P/E
P/E
Price to Earnings
9.5
vs History
6
vs Industry
Median 3Y
-5.6
Median 5Y
-2
Industry
20.6
Forward
-4.5
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
Median 3Y
-9
Median 5Y
-3.1
Industry
15.5
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-8.1
Median 5Y
-5.4
Industry
23
More Details
103.7
P/B
P/B
Price to Book Value
103.7
vs History
6
vs Industry
Median 3Y
-4.8
Median 5Y
0.9
Industry
1.9
More Details
3.5
EV/S
EV/S
Enterprise Value to Sales
3.5
vs History
87
vs Industry
7
Median 3Y
12.9
Median 5Y
7.4
Industry
2.5
Forward
14.6
More Details
3.5
EV/GP
EV/GP
Enterprise Value to Gross Profit
3.5
vs History
87
vs Industry
6
Median 3Y
13.9
Median 5Y
7.7
Industry
4.9
More Details
6.8
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
6.8
vs History
6
vs Industry
Median 3Y
-9.5
Median 5Y
-3.2
Industry
12.6
Forward
-6.4
More Details
6.8
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
6.8
vs History
6
vs Industry
Median 3Y
-9.3
Median 5Y
-3.1
Industry
15.7
Forward
-7.8
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
Median 3Y
-10.6
Median 5Y
-4.9
Industry
14
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
Median 3Y
-10.6
Median 5Y
-4.8
Industry
17.7
More Details
3.5
EV/IC
EV/IC
Enterprise Value to IC
3.5
vs History
47
vs Industry
5
Median 3Y
8.5
Median 5Y
3.4
Industry
1.8
More Details

Multiples Across Competitors

NWRN Competitors Multiples
Newron Pharmaceuticals SpA Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
IT
Newron Pharmaceuticals SpA
SIX:NWRN
142.3m CHF 2.9 9.5 6.8 6.8
US
Eli Lilly and Co
NYSE:LLY
838.1B USD 18.6 79.1 45.9 50.7
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
372.1B USD 4.2 17.1 12.4 16.3
DK
Novo Nordisk A/S
CSE:NOVO B
1.8T DKK 6.2 17.7 11.7 13.4
CH
Roche Holding AG
SIX:ROG
208.3B CHF 3.4 25.2 9.5 11.1
CH
Novartis AG
SIX:NOVN
187.4B CHF 4.4 19 11.5 14.7
UK
AstraZeneca PLC
LSE:AZN
161.3B GBP 4 30.5 126.2 192.7
US
Merck & Co Inc
NYSE:MRK
209.1B USD 3.3 12 8.6 10.3
IE
Endo International PLC
LSE:0Y5F
163.5B USD 70.5 -56 261.3 655.3
FR
Sanofi SA
PAR:SAN
115.8B EUR 1.3 9.1 5 5.9
P/E Multiple
Earnings Growth PEG
IT
Newron Pharmaceuticals SpA
SIX:NWRN
Average P/E: 24.4
9.5
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
79.1
49%
1.6
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
17.1
27%
0.6
DK
Novo Nordisk A/S
CSE:NOVO B
17.7
18%
1
CH
Roche Holding AG
SIX:ROG
25.2
32%
0.8
CH
Novartis AG
SIX:NOVN
19
17%
1.1
UK
AstraZeneca PLC
LSE:AZN
30.5
36%
0.8
US
Merck & Co Inc
NYSE:MRK
12
18%
0.7
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -56 N/A N/A
FR
Sanofi SA
PAR:SAN
9.1
28%
0.3
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
IT
Newron Pharmaceuticals SpA
SIX:NWRN
Average EV/EBITDA: 395
6.8
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
45.9
31%
1.5
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.4
8%
1.6
DK
Novo Nordisk A/S
CSE:NOVO B
11.7
14%
0.8
CH
Roche Holding AG
SIX:ROG
9.5
6%
1.6
CH
Novartis AG
SIX:NOVN
11.5
5%
2.3
UK
AstraZeneca PLC
LSE:AZN
126.2
9%
14
US
Merck & Co Inc
NYSE:MRK
8.6
9%
1
IE
E
Endo International PLC
LSE:0Y5F
261.3
N/A N/A
FR
Sanofi SA
PAR:SAN
5
8%
0.6
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
IT
Newron Pharmaceuticals SpA
SIX:NWRN
Average EV/EBIT: 1 698.1
6.8
55%
0.1
US
Eli Lilly and Co
NYSE:LLY
50.7
33%
1.5
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.3
12%
1.4
DK
Novo Nordisk A/S
CSE:NOVO B
13.4
16%
0.8
CH
Roche Holding AG
SIX:ROG
11.1
8%
1.4
CH
Novartis AG
SIX:NOVN
14.7
8%
1.8
UK
AstraZeneca PLC
LSE:AZN
192.7
21%
9.2
US
Merck & Co Inc
NYSE:MRK
10.3
12%
0.9
IE
E
Endo International PLC
LSE:0Y5F
655.3
N/A N/A
FR
Sanofi SA
PAR:SAN
5.9
14%
0.4

See Also

Summary
NWRN intrinsic value, competitors valuation, and company profile.
DCF Valuation
NWRN stock valuation using Discount Cash Flow valuation method.
Relative Valuation
NWRN stock valuation using valuation multiples.
Wall Street Estimates
NWRN price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
NWRN stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 248,900+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.